Bioatla Inc

BCAB.US
Healthcare · Biotechnology
3.52
+0.12 (+3.53%)
USD · NASDAQ

Company Information

Company Name
Bioatla Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US09077B1044
CIK: 0001826892
CUSIP: 09077B104
Currency: USD
Full Time Employees: 41
Phone: 858 558 0708
Fiscal Year End: December
IPO Date: Dec 16, 2020
Description:

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Address:

11085 Torreyana Road, San Diego, CA, United States, 92121

People

Directors & Officers

Name Title Year Born
Dr. Jay M. Short Ph.D. Co-Founder, CEO & Chairman 1958
Dr. Eric L. Sievers M.D. Chief Medical Officer 1964
Ms. Susie Melody Senior Vice President of Human Resources NA
Dr. Cathy Chang Ph.D. Senior Vice President of Research & Development NA
Dr. Gerhard Frey Ph.D. Senior Vice President of Technology Development NA
Ms. Monica Sullivan Senior Vice President of Intellectual Property & Contracts NA
Ms. Sheri Lydick Chief Commercial Officer NA
Lisa M. Pelton Accounting Manager NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 26, 2023 Sylvia Mcbrinn N/A Purchase 80.00 $116.50 $9.32K
Dec 20, 2023 Jay M Phd Short N/A Purchase 1.00K $107.00 $107.00K
Dec 19, 2023 Lawrence Steinman N/A Purchase 400.00 $102.50 $41.00K
Sep 08, 2023 Sylvia Mcbrinn N/A Purchase 40.00 $127.00 $5.08K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Millennium Management LLC 2.76M Mar 31, 2026 3.32% $0.00 261.58%
Vanguard Group Inc 1.95M Dec 31, 2025 2.35% $0.00 0.00%
Vanguard Capital Management, LLC 1.65M Mar 31, 2026 1.99% $0.00 0.00%
Acadian Asset Management LLC 1.23M Mar 31, 2026 1.49% $0.00 0.00%
Geode Capital Management, LLC 689.18K Mar 31, 2026 0.83% $0.00 37.75%
Deutsche Bank AG 525.35K Mar 31, 2026 0.63% $0.00 0.00%
Renaissance Technologies Corp 510.51K Mar 31, 2026 0.62% $0.00 -27.81%
BlackRock Inc 480.93K Mar 31, 2026 0.58% $0.00 0.00%
Citadel Advisors Llc 435.68K Mar 31, 2026 0.53% $0.00 0.00%
UBS Group AG 375.57K Mar 31, 2026 0.45% $0.00 66.41%
Marshall Wace Asset Management Ltd 277.63K Mar 31, 2026 0.33% $0.00 -68.86%
Vanguard Fiduciary Trust Co 273.43K Mar 31, 2026 0.33% $0.00 0.00%
ADAR1 Capital Management LLC 228.11K Mar 31, 2026 0.27% $0.00 24.58%
State Street Corp 151.38K Mar 31, 2026 0.18% $0.00 0.00%
Northern Trust Corp 103.49K Mar 31, 2026 0.12% $0.00 0.00%
SIMPLEX TRADING, LLC 73.90K Mar 31, 2026 0.09% $0.00 -38.62%
Stonepine Capital Management Llc 65.39K Mar 31, 2026 0.08% $0.00 0.00%
XTX Topco Ltd 56.61K Mar 31, 2026 0.07% $0.00 -6.26%
Morgan Stanley - Brokerage Accounts 55.43K Mar 31, 2026 0.07% $0.00 26.97%
Mccormack Advisors International 51.50K Mar 31, 2026 0.06% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Xtrackers MSCI World Swap ETF 1C 147.69K 0.18% ▼ 0.63% Dec 31, 2025
2 Extended Equity Market Fund B 97.50K 0.12% ▲ 0.00% Dec 31, 2025
3 Extended Equity Market Fund E 97.50K 0.12% ▲ 0.00% Dec 31, 2025
4 NT Ext Eq Mkt Idx Fd DC Lending Tier 5 27.54K 0.03% ▲ 0.70% Mar 31, 2026
5 BSF Systematic US Eq Abs Ret A2 USD 10.53K 0.01% ▲ 0.00% Dec 31, 2025
6 Vanguard Institutional Extnd Mkt Idx Tr 9.16K 0.55% ▲ 0.00% Jun 30, 2026
7 Fidelity Extended Market Index 6.13K 0.37% ▼ 30.87% May 31, 2026
8 U.S. Equity Market Fund B 6.01K 0.01% ▲ 0.00% Dec 31, 2025
9 U.S. Equity Market Fund 6.01K 0.01% ▲ 0.00% Dec 31, 2025
10 SSgA U.S. Total Market Index Strategy 4.98K 0.01% ▼ 1.79% Sep 30, 2025

Financial Highlights

Market Cap: $5.64M
EBITDA: $-49.59M
Book Value: $-22.48
Earnings/Share: $-41.56
Profit Margin: 0.00%
Operating Margin: -2,494.95%
ROA (TTM): -133.12%
ROE (TTM): -813.88%
Revenue (TTM): $2.00M
Revenue/Share (TTM): $1.59
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 31.60%

Valuation Metrics

Enterprise Value: $9.73M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 1.66M
Shares Float: 1.37M
% Insiders: 545.80%
% Institutions: 2,248.60%
Short % Float: 7.72%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$2.00M
Cost of Goods Sold
adjust
$-43.07M
Gross Profit
subtotal
$-41.07M
SG&A
adjust
$-17.63M
R&D
adjust
$-43.57M
Operating Income
subtotal
$-59.31M
Other / Non-Operating Items
adjust
$-302.00K
Net Income
subtotal
$-59.61M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BCAB.US!